Relmada Therapeutics CMO-Urology buys 55,000 shares in open market on Aug 29, 2025

RELMADA THERAPEUTICS, INC.

Raj S. Pruthi, MD, Chief Medical Officer-Urology, purchased 55,000 shares of RLMD common stock on August 29, 2025.
The purchase was executed via open market transactions; no specific price disclosed in filing.
Insider purchase may signal management confidence in the company's outlook.

item 7.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.